×
Entrez Id: 3106
Gene Symbol: HLA-B
HLA-B
0.100
GeneticVariation
group
GWASCAT
An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma.
27436580 2016
LINC02571
0.100
GeneticVariation
group
GWASCAT
An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma.
27436580 2016
×
Entrez Id: 3265
Gene Symbol: HRAS
HRAS
0.100
GeneticVariation
group
CLINVAR
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
26619011 2016
×
Entrez Id: 3105
Gene Symbol: HLA-A
HLA-A
0.100
GeneticVariation
group
GWASCAT
An extended genome-wide association study identifies novel susceptibility loci for nasopharyngeal carcinoma.
27436580 2016
×
Entrez Id: 4893
Gene Symbol: NRAS
NRAS
0.100
GeneticVariation
group
CLINVAR
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
26619011 2016
CDKN2B-AS1
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
20512145 2010
×
Entrez Id: 3106
Gene Symbol: HLA-B
HLA-B
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
20512145 2010
LINC02571
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
20512145 2010
×
Entrez Id: 3105
Gene Symbol: HLA-A
HLA-A
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
20512145 2010
×
Entrez Id: 3680
Gene Symbol: ITGA9
ITGA9
0.100
GeneticVariation
group
GWASCAT
A genome-wide association study identifies ITGA9 conferring risk of nasopharyngeal carcinoma.
19478819 2009
×
Entrez Id: 3105
Gene Symbol: HLA-A
HLA-A
0.100
GeneticVariation
group
GWASCAT
Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3.
19664746 2009
×
Entrez Id: 4486
Gene Symbol: MST1R
MST1R
0.100
Biomarker
group
HPO
×
Entrez Id: 79728
Gene Symbol: PALB2
PALB2
0.100
CausalMutation
group
CLINVAR
×
Entrez Id: 2067
Gene Symbol: ERCC1
ERCC1
0.010
AlteredExpression
group
BEFREE
Immunohistochemical analysis was used to assess the ERCC1 expression in nasopharyngeal tumor tissues.
29578165 2018
×
Entrez Id: 3605
Gene Symbol: IL17A
IL17A
0.010
AlteredExpression
group
BEFREE
Expression of miR-135a in the cancer cells isolated from nasopharyngeal tumors was significantly lower than that in NP69 cells, and suppression of IL-17 by miR-135a mimic resulted in significant inhibition of NPC cell proliferation.
29734196 2018
×
Entrez Id: 6422
Gene Symbol: SFRP1
SFRP1
0.010
PosttranslationalModification
group
BEFREE
KL and SFRP1 methylation were more predominant in nasopharyngeal tumors (P = 0.001 and P = 0.031 respectively).
28812223 2017
×
Entrez Id: 57016
Gene Symbol: AKR1B10
AKR1B10
0.010
AlteredExpression
group
BEFREE
To examine the expression of AKR1B10 at mRNA and protein levels in nasopharyngeal tumors and correlate its expression with clinicopathological parameters.
26835713 2016
×
Entrez Id: 6774
Gene Symbol: STAT3
STAT3
0.010
Biomarker
group
BEFREE
EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumor -initiating cells through attenuation of STAT3 activation.
24966947 2014
×
Entrez Id: 83596
Gene Symbol: BCL2L12
BCL2L12
0.010
AlteredExpression
group
BEFREE
Higher BCL2L12 mRNA levels were detected in undifferentiated carcinomas of the nasopharynx, rather than in nonkeratinizing nasopharyngeal tumors (P = 0.045).
21152697 2011
×
Entrez Id: 596
Gene Symbol: BCL2
BCL2
0.010
Biomarker
group
BEFREE
Survival analysis demonstrated that patients with BCL2 -positive nasopharyngeal tumors have significantly shorter disease-free and overall survival (p = 0.011 and p = 0.028, respectively).
20514538 2010
×
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.010
GeneticVariation
group
BEFREE
Increase of the therapeutic effect by treating nasopharyngeal tumor with combination of HER-2 siRNA and paclitaxel.
20198351 2010
×
Entrez Id: 3082
Gene Symbol: HGF
HGF
0.010
Biomarker
group
LHGDN
Hepatocyte growth factor enhances proteolysis and invasiveness of human nasopharyngeal cancer cells through activation of PI3K and JNK.
18789327 2008
×
Entrez Id: 308
Gene Symbol: ANXA5
ANXA5
0.010
AlteredExpression
group
LHGDN
Proteomic comparison of nasopharyngeal cancer cell lines C666-1 and NP69 identifies down-regulation of annexin II and beta2-tubulin for nasopharyngeal carcinoma.
18384219 2008
×
Entrez Id: 5216
Gene Symbol: PFN1
PFN1
0.010
AlteredExpression
group
LHGDN
Proteomic comparison of nasopharyngeal cancer cell lines C666-1 and NP69 identifies down-regulation of annexin II and beta2-tubulin for nasopharyngeal carcinoma.
18384219 2008
×
Entrez Id: 2697
Gene Symbol: GJA1
GJA1
0.010
AlteredExpression
group
BEFREE
Thus, the amplified Cx43 expression by an antitumor agent, an HDAC inhibitor, may have great potential as a growth inhibitor for nasopharyngeal tumors .
17487363 2007